Home / Resources / Q4 Outlook Report: Key Industry Drugs, Devices & Deals
Q4 Outlook Report: Key Industry Drugs, Devices & Deals

In this report, we cover catalysts from 24 drugs, devices, diagnostics, and deals expected to occur in Q4 2024.

Discover more by downloading the report.

PDF previews of the Q4 2024 Outlook Report.
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.
Related products
Expert analyst presenting data insights on a projected screen.
Biomedtracker
Real-time tracking and analysis of the drug development pipeline
Healthcare professionals using the latest and innovative medical device technology with 3D modeling.
Meddevicetracker
A 360° view of medical device markets, companies and products
Healthcare professional monitoring and analyzing R and D trends.
Pharmaprojects
The industry standard for tracking and analyzing the global drug R&D landscape

Related resources

''
Clinical

Pharma R&D Annual Review 2024

For over 30 years, the Pharma R&D Annual Review has tracked how the climate is shifting. Browse our resources to help you navigate the climate.

Citeline professional presenting the Q3 2024 Outlook Report provided by Biomedtracker.
JUL 08, 2024
Report
Commercial

Q3 2024 Outlook Report

In this report, we cover catalysts from 24 drugs, devices, diagnostics, and deals expected to occur in Q3 2024.

Stacks of coins arranged in ascending order with a white arrow and line graph overlay indicating growth
JUN 11, 2024
eBook
Commercial

Billion Dollar Blueprint: The Journey to Blockbuster Status

A deep dive into the dynamics of blockbuster drugs. Using data from Evaluate Pharma, Scrip surveys the existing field of these top-tier products, examines the role that multiple indications play and the time it takes to reach blockbuster status, and considers whether there is an advantage for in-house or external assets.

View all